On July 19, 2018 Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, reported the appointment of Anthony G. Quinn, M.B Ch.B, Ph.D. as the Company’s President and Chief Executive Officer, effective immediately (Press release, Aeglea BioTherapeutics, JUL 19, 2018, View Source [SID1234527782]). Dr. Quinn has been a member of the Company’s Board of Directors since 2016 and had served as interim CEO since July 2017.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Aeglea has made great progress over the last 12 months with compelling data from the Company’s lead program pegzilarginase under Anthony’s leadership," said Armen Shanafelt, Ph.D., Chairman of Aeglea’s Board of Directors. "The Board is looking forward to continue working with him as we progress through the next phase of Aeglea’s evolution. In addition to his technical expertise, Anthony has shown himself to be an extremely talented executive who focuses on patients and on delivering shareholder value. As a Board, we are excited by both the potential of Aeglea’s pipeline and the clinically relevant treatment effects seen with pegzilarginase in patients with Arginase 1 Deficiency."
"I am honored to have the opportunity to lead Aeglea at this stage in the Company’s development and thrilled to be able to shape the next stage of our journey with the Aeglea team as we advance therapies with the potential to improve the lives of patients with devastating diseases," said Dr. Quinn. "The Company occupies a unique and exciting area in the biotechnology industry with its focus on discovering novel human enzyme-based therapeutics for patients with rare genetic diseases and cancer. I believe we are now well positioned for future growth with our pipeline programs and our expanded in-house drug-hunting capabilities."
Prior to joining Aeglea, Dr. Quinn served as executive vice president, head of research and development, and chief medical officer at Synageva Biopharma Corp. until the company’s acquisition by Alexion Pharmaceuticals in 2015. Dr. Quinn previously served as worldwide head of clinical research and exploratory development for inflammatory diseases at Roche. He also was a professor of dermatology at Barts and The London School of Medicine. Dr. Quinn received his Bachelor of Medical Science and his M.B Ch.B from the University of Dundee, and his Ph.D. from the University of Newcastle upon Tyne. Dr. Quinn completed a postdoctoral fellowship at the University of California San Francisco and is a fellow of the Royal College of Physicians London.